Program
JSKN016
A development code. Also written as “JSKN016 Injection” and “JSKN016 injection”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms, led by Alphamab Oncology.
Furthest: phase 3, since Mar 17, 20265 company-led studies, 5 open or runningNext primary completion: Jun 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alphamab Oncology | 55 open or running | phase 3since Mar 17, 2026 | Apr 28, 2024 | Jun 30, 2027phase 2 · NCT06942234 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 28, 2024First study: phase 1 study in Advanced Malignant Solid TumorFirst studyNCT06592417 · 140 planned · China
- Dec 30, 2024Phase 2 study in Advanced Non-small Cell Lung CancerNCT06775483 · 220 planned
- Mar 5, 2025Phase 1 study in Advanced Non-small Cell Lung CancerNCT06868732 · 288 planned · China
- Apr 10, 2025Phase 2 study in Inoperable Locally Advanced HER2-Negative Breast CancerNCT06942234 · 180 planned · China
- Mar 17, 2026Phase 3 study in Triple Negative Breast NeoplasmsPhase 3 reachedNCT07533123 · 364 planned · China
Ahead
- Jun 30, 2027Primary completion: phase 2 study in Inoperable Locally Advanced HER2-Negative Breast CancerNCT06942234
- Jun 30, 2027Primary completion: phase 2 study in Advanced Non-small Cell Lung CancerNCT06775483
- Jun 30, 2028Primary completion: phase 1 study in Advanced Non-small Cell Lung CancerNCT06868732
- Mar 17, 2029Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT07533123
TargetBeta
“JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07533123Triple Negative Breast Neoplasms · China | 3 | Recruiting | Mar 17, 2029 | 364 |
| NCT06942234Inoperable Locally Advanced HER2-Negative Breast Cancer · China | 2 | Recruiting | Jun 30, 2027 | 180 |
| NCT06868732Advanced Non-small Cell Lung Cancer · China | 1 | Recruiting | Jun 30, 2028 | 288 |
| NCT06775483Advanced Non-small Cell Lung Cancer | 2 | Not yet recruiting | Jun 30, 2027 | 220 |
| NCT06592417Advanced Malignant Solid Tumor · China | 1 | Recruiting | May 17, 2026 | 140 |
How it is read
Names in the registry
- “JSKN016”, 3 entries
- “JSKN016 Injection”, 1 entry
- “JSKN016 injection”, 1 entry
Codes read as this program: JSKN016.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Triple Negative Breast Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.